Possible applications of antibodies or their genes in cancer therapy.
In this review article the possible applications of anti-tumor-associated antigen (TAA) antibodies in the therapy of cancer have been summarized. First, recombinant monoclonal antibodies (MAbs) are increasingly being used as therapeutic agents, especially in combination with anti-cancer drugs. Second, conjugation of antibody therapy with toxins or radioisotopes offers more therapeutic approaches. Third, development of cytotoxic T-lymphocyte (CTL) or natural killer (NK)-cell populations with anti-TAA antibody activity may be important for the success of cancer immunotherapy because the downregulated HLA class I molecules and the non-ubiquitous expression of NK receptor ligands in tumor tissues constitute the major tumor escape mechanism facing tumor-specific CTL- and/or NK-cell-mediated responses. Finally, in cancer gene therapy, the strategies to target viral vectors carrying therapeutic genes to tumor tissues by modifying the tropisms with MAbs or their genes against TAAs are also very promising.
Kuroki
Masahide
M
Department of Biochemistry, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. kurokima@fukuoka-u.ac.jp
Huang
Jian
J
Shibaguchi
Hirotomo
H
Tanaka
Toshihiro
T
Zhao
Jun
J
Luo
Naixiang
N
Hachimine
Ken
K
Kinugasa
Tetsushi
T
Maekawa
Shin-Ichi
S
Enatsu
Sotaro
S
Hamanaka
Wakako
W
Fukami
Tatsuya
T
Kuroki
Motomu
M
D000818:Animals; D000906:Antibodies / Q000235:genetics* / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
D000906:Antibodies; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm